Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

NSCLC Stage IV Clinical Trial

Official title:

A Phase II Study of Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05215548
• Other study ID #: 202107141RINB
• Status: Recruiting
• Phase: Phase 2
• Start date: September 27, 2021
• Est. completion date: July 2026

Study information

• Verified date: April 2023
• Source: National Taiwan University Hospital
• Contact: Jin-Shing Chen, M.D., Ph.D.
• Phone: 886-2-2322-0322
• Email: chenjs[@]ntu.edu.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong survival. This project is supposed to establish a new treatment protocol for stage IV NSCLC with EGFR mutation.

Description:

In Taiwan, non-small cell lung cancer (NSCLC) has been the leading cause of cancer death, making a phenomenal impact on public health. By understanding the oncogenic driver mutations of NSCLC (e.g. EGFR mutation or ALK rearrangement), the target therapy has taken the place of chemotherapy for its effectiveness and specificity, becoming the new standard of care for stage IV NSCLC. Despite the progress of medical treatment, the majority of patients with stage IV NSCLC still underwent disease progression after a period of time. Noticeably, more than half of the progression was restricted to the original sites of the tumor. It brings up the hypothesis that a combination of local consolidative therapy (e.g. surgery or radial therapy) and medical treatment could be beneficial for these patients. This has been advocated by the latest clinical trials as well. Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong the progression-free survival. This project is supposed to establish a new treatment protocol for stage IV NSCLC with EGFR mutation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: July 2026
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed non-small cell lung cancer
• Stage IV non-small cell lung cancer which is amenable to thoracic surgery
• Patients must have one of the following:NSCLC which harbors EGFR exon 19 deletion or L858R mutation.
• Eastern Cooperative Oncology Group (ECOG) performance status =< 1
• Candidate for therapeutic intent surgery to at least one site of disease
• Signed and dated written informed consent prior to admission to the study in accordance with International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)-Good Clinical Practice (GCP) guidelines and to the local legislation

Exclusion Criteria:

• Life expectancy <= 12 weeks
• With underlying diseases such as moderate to severe Chronic Obstructive Pulmonary Disease or tuberculosis
• With uncontrol diseases including acute infection, unstable angina or angina in recent 3 months, Heart failure(NYHA=2), myocardial infarction in recent 6 months, severe arrhythmia, moderate to severe cirrhosis, moderate to severe chronic renal insufficiency, immune insufficiency, any systemic disease with poor prognosis after treatment.
• With Cerebrovascular Accident complicated dependent activities of daily living.
• Any other cancer with active treatment in recent 5 years.
• receive thoracic surgery in the ipsilateral site with the lung cancer previously. (the biopsy surgery required for the diagnosis of lung cancer was not excluded)
• pregnant or breast-feeding woman
• Previous treatment with other EGFR TKI. NOTE: Patients who are receiving initial afatinib (6-12 weeks) outside this study are not excluded
• Disagree to receive Next Generation Sequencing for the lesion specimen after surgery.

Related Conditions & MeSH terms

• NSCLC Stage IV

Intervention

Procedure:
• therapeutic thoracic surgery
The surgery group would receive therapeutic thoracic surgery with maximal local regional control intent and would prescribe with maintenance afatinib therapy after operation. Patients continue afatinib 1 to 2 weeks after surgery.

Drug:
• Afatinib
The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).

Locations

Country	Name	City	State
Taiwan	National Taiwan University Cancer Center	Taipei
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	2 year progression free survival rate	Will be estimated using Kaplan-Meier method. The stratified log-rank test will be performed to test the difference in time-to-event distributions between treatment groups. Stratified Cox proportional hazards model will be utilized to include multiple covariates in the time-to-event analysis and to estimate hazard ratios.	start date of afatinib assessed up to 2 years
Secondary	Progression free survival	Will be estimated using Kaplan-Meier method. The stratified log-rank test will be performed to test the difference in time-to-event distributions between treatment groups. Stratified Cox proportional hazards model will be utilized to include multiple covariates in the time-to-event analysis and to estimate hazard ratios.	From the start date of afatinib assessed up to 4 years
Secondary	Overall survival	Will be estimated using Kaplan-Meier method. The stratified log-rank test will be performed to test the difference in time-to-event distributions between treatment groups. Stratified Cox proportional hazards model will be utilized to include multiple covariates in the time-to-event analysis and to estimate hazard ratios.	From the start date of afatinib assessed up to 4 years
Secondary	Treatment-related adverse events	It refers to the number of adverse events related to afatinib monotherapy or platinum-based chemotherapy as evaluated according to CTCAE v4.0.	From the start date of afatinib assessed up to 4 years
Secondary	R0 resection rate	It is defined as the proportion of patients with negative surgical margin and no residual found under microscope after resection in all patients who have completed the thoracic surgery treatment.	From the start date of afatinib assessed up to 12 weeks
Secondary	resistant mutation events	Patient in the surgery and control group would receive next generation sequencing for tumor mutation check. The surgery group would receive next generation sequencing twice (1. after surgery 2. progression of disease or unacceptable toxicity.) The control group would receive next generation sequencing once (progression of disease or unacceptable toxicity.)	12 weeks to 4 years